Wound Healing Modulation after Pterygium Surgery Using Photodynamic Therapy. A Clinical Pilot Study
Hueber A.1, Grisanti S.2, Diestelhorst M.1
1Department of Anterior Segment Surgery, Center of Ophthalmology, University of Cologne; 2Center of Ophthalmology, Eberhard-Karls University Tuebingen
Purpose: This study was performed to evaluate the safety and efficacy of the carboxyfluoresceinester BCECF-AM in the adjuvante therapy during surgery for pterygium.
Method: In this non-randomized, prospective clinical trial 19 eyes with nasally located primary pterygium were included. All eyes were operated with the bare sclera surgical technique. Seven eyes received in addition treatment with BCECF-AM solution and blue light. All patients were evaluated at least on the first day and than after one week, after one and three month and after one year after surgery. Any postoperative re-growth of fibro-vascular tissue, ignoring the limbus and growing onto the cornea was defined as recurrence.
Results: The intra-operative application of BCECF-AM solution, compared to controls, did not cause any other side effects, even no anterior chamber flare. The control group had a rate of recurrence of 0% (0 of 12) after 3 months and 91% (11 of 12) after 1 year. The BCECF-AM group had a rate of recurrence of 14.2% (1 of 7) after 3 months and 71.4% (5 of 7) after 1 year.
Conclusions: The applied technique appears to be a safe procedure but is associated with a relatively high rate of recurrence.
Zurück | Back